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Therapy of experimental allergic encephalomyelitis under circumstances relevant to 
human Multiple Sclerosis. Part III 
 
Experimental allergic encephalomyelitis (EAE) is an inflammatory disease of the central nervous 
system (CNS) that resembles human multiple sclerosis (MS). EAE and MS develop when 
proteins of the myelin sheath that covers axons are released and encounter cells of the immune 
system such as T lymphocytes. Activation of these lymphocytes will trigger inflammation that 
destroys the myelin leading to clinical signs that manifest mostly in the form of motion 
impairment and muscle paralysis. Inactivation of myelin specific lymphocytes is currently 
viewed as a means to halt immune attack against the brain and reverse the course of disease. 
Previous research in our lab has shown that peptide delivery on immunoglobulin (Ig) is effective 
against EAE. This method of treatment, however, presents a clinical challenge for use in humans, 
because it involves intraperitoneal injection of the chimeric Ig (Ig-MOG). We have determined 
that the oral route, which is more practical, yields comparable results against the disease. This 
model is also useful for investigation of mechanisms of oral tolerance. 
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